Ningbo MedicalSystem Biotechnology Co Ltd (SHE:300439) — Market Cap & Net Worth
Market Cap & Net Worth: Ningbo MedicalSystem Biotechnology Co Ltd (300439)
Ningbo MedicalSystem Biotechnology Co Ltd (SHE:300439) has a market capitalization of $567.44 Million (CN¥3.88 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #11881 globally and #3645 in its home market, demonstrating a 3.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ningbo MedicalSystem Biotechnology Co Ltd's stock price CN¥10.09 by its total outstanding shares 384318815 (384.32 Million). Analyse Ningbo MedicalSystem Biotechnology Co Lt operating cash flow efficiency to see how efficiently the company converts income to cash.
Ningbo MedicalSystem Biotechnology Co Ltd Market Cap History: 2015 to 2026
Ningbo MedicalSystem Biotechnology Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.12 Billion to $567.44 Million (-10.58% CAGR).
Ningbo MedicalSystem Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ningbo MedicalSystem Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.34x
Ningbo MedicalSystem Biotechnology Co Ltd's market cap is 0.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.28x
Ningbo MedicalSystem Biotechnology Co Ltd's market cap is 2.28 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.12 Billion | $683.14 Million | $161.27 Million | 3.10x | 13.12x |
| 2016 | $1.60 Billion | $1.06 Billion | $174.49 Million | 1.51x | 9.17x |
| 2017 | $1.01 Billion | $2.58 Billion | $229.70 Million | 0.39x | 4.41x |
| 2018 | $714.78 Million | $3.14 Billion | $241.17 Million | 0.23x | 2.96x |
| 2019 | $734.33 Million | $3.13 Billion | -$576.63 Million | 0.23x | N/A |
| 2020 | $987.21 Million | $2.30 Billion | $299.48 Million | 0.43x | 3.30x |
| 2021 | $1.16 Billion | $2.25 Billion | $179.49 Million | 0.52x | 6.47x |
| 2022 | $642.19 Million | $2.49 Billion | $198.53 Million | 0.26x | 3.23x |
| 2023 | $643.17 Million | $1.89 Billion | $256.55 Million | 0.34x | 2.51x |
| 2024 | $587.69 Million | $1.74 Billion | $258.00 Million | 0.34x | 2.28x |
Competitor Companies of 300439 by Market Capitalization
Companies near Ningbo MedicalSystem Biotechnology Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Ningbo MedicalSystem Biotechnology Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Ningbo MedicalSystem Biotechnology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Ningbo MedicalSystem Biotechnology Co Ltd's market cap moved from $2.12 Billion to $ 567.44 Million, with a yearly change of -10.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥567.44 Million | +2.44% |
| 2025 | CN¥553.94 Million | -5.74% |
| 2024 | CN¥587.69 Million | -8.63% |
| 2023 | CN¥643.17 Million | +0.15% |
| 2022 | CN¥642.19 Million | -44.66% |
| 2021 | CN¥1.16 Billion | +17.55% |
| 2020 | CN¥987.21 Million | +34.44% |
| 2019 | CN¥734.33 Million | +2.74% |
| 2018 | CN¥714.78 Million | -29.51% |
| 2017 | CN¥1.01 Billion | -36.65% |
| 2016 | CN¥1.60 Billion | -24.32% |
| 2015 | CN¥2.12 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Ningbo MedicalSystem Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $567.44 Million USD |
| MoneyControl | $567.44 Million USD |
| MarketWatch | $567.44 Million USD |
| marketcap.company | $567.44 Million USD |
| Reuters | $567.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more